Back

Use of human biological material (release review)

Use of human biological material (release review)

Approval from the TCBio via a release review is necessary prior to use of:

  • human biological material from biobanks or sub-biobanks
  • residual material (fresh or otherwise) from diagnostic procedures or treatment
  • human biological material left over from WMO research
  • human biological material from collections not yet registered with the Central Biobank

Review uitklapper, klik om te openen

The TCBio reviews the intended use of human biological material based on the release criteria of the Biobank Regulations of UMC Utrecht (Article 10). 

Always use the most recent version of the release protocol. This form has been brought in line with the Biobank Regulations.

For the compilation of a new file, for your response to questions or for amendments to approved files, please refer to the section under ‘File’. 

An important part of the review relates to the study design. For advice on study design and statistical methods, please contact Julius Support for Research & Trials.

Meer informatie

File uitklapper, klik om te openen

The file for a new release review will consist of the following documents in PDF format, with the file names stated:

Document  Explanation
(enter the requested details where it says ‘version ...’ and ‘[dd-mm-yy]’)
A1 Cover letter / e-mail from applicant dated [dd-mm-yy]A separate cover letter (paper version) with explanatory notes is optional when submitting a file. Any explanation can also be provided in the cover e-mail.
C3 Release protocol version ... dated [dd-mm-yy]

Link to release protocol template: 

C3_Uitgifteprotocol_v[x]_dd[dd-mm-jj].docx.  New in version of December 2020: amended in C3, sections D and E. 

For Section D (privacy): see RNAseq statement* below

Note: In the PDF file all text in the fields must be clearly legible

E1. Biobank information letter version ... dated [dd-mm-yy] for review based on consent already given by the donor (if applicable)
E2. Consent form version ... dated [dd-mm-yy] for review based on consent already given by the donor (if applicable)
K3. Material Transfer Agreement or Clinical Trial Agreement of [name of company or centre] dated [dd-mm-yy]

(if applicable)

Signed MTA must be received before approval can be given.  

*RNA sequencing: patient consent is necessary

RNA sequencing (RNAseq) is frequently used to generate RNA expression profiles in cells. The RNA sequence that is generated as part of this technique could be attributed to a natural person. The committee bases this statement on the following article: Nat Genet. 2012 May;44(5):603-8. doi: 10.1038/ng.2248.

Therefore, in line with the General Data Protection Regulation (GDPR), a patient's consent is needed to perform RNAseq. The opt-out rule for secondary use of residual human tissue provides insufficient ground in these cases.

A response to questions from the Committee will consist of the following documents in PDF format; also follow the submission instructions provided in the e-mail received with the Committee’s first questions:

DocumentExplanation
(enter the requested details where it says ‘[dd-mm-yy]’)
A1. Response letter from applicant dated [dd-mm-yy]= item-by-item response to the Committee’s questions
All documents which have changed in connection with the response to the questions Always visualise the changes with the track changes functionality, and adjust the version number and date

Approach for amendments to a release protocol:

Document Explanation
(enter the requested details where it says ‘version ...’ and ‘[dd-mm-yy]’)
A1 Cover letter / e-mail from applicant dated [dd-mm-yy]Letter with a summary of changes and a substantiation
C4. Release protocol amendment version ... dated [dd-mm-yy]Visualise the changes with the track changes functionality in the approved biobank protocol, change the file name as stated on the left-hand side, and have it signed again for approval of the changes

Other documents which 

1) have changed in connection with the amendment 

 and/or

2) are necessary for a new assessment of the amendment to the study (e.g. information letter)


1)  Visualise the changes with the track changes functionality and adjust the version number and date


2) Example: material will also be sent abroad as a result of the amendment > the original information letter is needed to assess whether the consent obtained is sufficient for this 

Findings during the research

The approach for the submission and review of findings has been laid down in a SOP:

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

UMC Utrecht maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid